The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study
Open accessAbstract
Objective: Immune checkpoint inhibitors (ICI s) for cancer therapy frequently induce immune‐related adverse effects (IRAE s). Therefore, most patients with preexisting autoimmune diseases have been excluded from clinical trials of ICI s. This study was undertaken to evaluate the safety and efficacy of ICI s in patients with preexisting autoimmune disease and cancer. Methods: A retrospective cohort study was conducted from January 2017 to January 2018 via 3 French national networks of experts in oncology and autoimmunity. Adults with preexisting autoimmune disease who were receiving ICI s were assessed for the occurrence of flare of preexisting autoimmune disease, other IRAE s, and cancer response. Results: The study included 112 patients who were followed up for a median of 8 months. The most frequent preexisting autoimmune diseases were psoriasis (n = 31), rheumatoid arthritis (n = 20), and inflammatory bowel disease (n = 14). Twenty‐four patients (22%) were receiving immunosuppressive therapy at ICI initiation. Autoimmune disease flare and/or other IRAE(s) occurred in 79 patients (71%), including flare of preexisting autoimmune disease in 53 patients (47%) and/or other IRAE(s) in 47 patients (42%), with a need for immunosuppressive therapy in 48 patients (43%) and permanent discontinuation of ICI in 24 patients (21%). The median progression‐free survival was shorter in patients receiving immunosuppressive therapy at ICI initiation (3.8 months versus 12 months; P = 0.006), confirmed by multivariable analysis. The median progression‐free survival was shorter in patients who experienced a flare of preexisting autoimmune disease or other IRAE, with a trend toward better survival in the subgroup without immunosuppressant use or ICI discontinuation. Conclusion: Our findings indicate that flares or IRAE s occur frequently but are mostly manageable without ICI discontinuation in patients with a preexisting autoimmune disease. Immunosuppressive therapy at baseline is associated with poorer outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 5×
“1) 6 (86) 0 (0) 1 (33) 1 (50) Immunosuppressive therapy for flare 28 (54) 7 (33) 10 (83) 5 (71) 0 (0) 3 (100) 1 (50) Glucocorticoids (any dose) 24 (86) 3 (43) 10 (100) 5 (100) 0 (0) 3 (100) 1 (100) Glucocorticoids 0–15 mg/day 13 (57) 3 (100) 6 (67) 0 (0) 0 (0) 3 (100) 0 (0) Glucocorticoids 20–40 mg/day 4 (17) 0 (0) 2…”
InfluentialNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 4×
“of previous courses of treatment None 49 (44) 49 (74) 0 (0) 0 (0) 0 (0) 1 36 (32) 13 (20) 18 (46) 3 (75) 2 (100) ≥2 26 (23) 4 (6.”
InfluentialSelf-citationCancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Self-citationImmune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Self-citationPhan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575 · cited 3×
“of previous courses of treatment None 49 (44) 49 (74) 0 (0) 0 (0) 0 (0) 1 36 (32) 13 (20) 18 (46) 3 (75) 2 (100) ≥2 26 (23) 4 (6.”
Schachter, J., Ribas, A., Long, G. V., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31601-x · Cited by 1,225
Self-citationSafety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158
Self-citationArbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., Martínez-Bernal, G., Ferrara, R., Lai, W. V., Hendriks, L. E. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0006 · Cited by 1,071 · cited 6×
“001) in a multivariable analysis incorporating smoking status, performance status score, and history of brain metastasis (46).”
BackgroundInfluentialHorvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
Haratani, K., Hayashi, H., Chiba, Y., Kudo, K., Yonesaka, K., Kato, R., Kaneda, H., Hasegawa, Y., Tanaka, K., Takeda, M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2925 · Cited by 1,003
Chen, P.-L., Roh, W., Reuben, A., Cooper, Z. A., Spencer, C. N., Prieto, P. A., Miller, J. P., Bassett, R. L., Gopalakrishnan, V., Wani, K., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1545 · Cited by 988 · cited 3×
“Flare of preexisting autoimmune disease 53 (47) 21 (68) 12 (60) 7 (50) 1 (14) 3 (43) 2 (40)”
BackgroundMenzies, A. M., Johnson, D. B., Ramanujam, S., Atkinson, V. G., Wong, A. N. M., Park, J. J., McQuade, J. L., Shoushtari, A. N., Tsai, K. K., Eroglu, Z., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw443 · Cited by 817 · cited 7×
“Previous immunosuppressive therapy 9 (30) 14 (70) 7 (54) 4 (57) 4 (80) 2 (67) Glucocorticoids 1 (11) 5 (36) 3 (43) 2 (50) 4 (100) 0 (0) csDMARD 6 (67) 13 (93) 6 (86) 3 (75) 0 (0) 2 (100) bDMARD 2 (22) 4 (29) 1 (14) 0 (0) 0 (0) 1 (50) Acitretin 4 (44) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Discontinuation of immunosuppressants…”
BackgroundInfluentialTreatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review
Friedman, C. F., Proverbs-Singh, T. A., & Postow, M. A. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1051 · Cited by 802
Hua, C., Boussemart, L., Mateus, C., Routier, E., Boutros, C., Cazenave, H., Viollet, R., Thomas, M., Roy, S., Benannoune, N., et al. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.2707 · Cited by 655
Self-citationIpilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642 · cited 6×
“ICI used Ipilimumab 14 (13) 14 (21) 0 (0) 0 (0) 0 (0) Nivolumab 63 (56) 22 (33) 39 (98) 2 (50) 0 (0) Pembrolizumab 27 (24) 27 (41) 0 (0) 0 (0) 0 (0) Combination of ipilimumab and nivolumab 3 (2.”
BackgroundInfluentialTeulings, H.-E., Limpens, J., Jansen, S. N., Zwinderman, A. H., Reitsma, J. B., Spuls, P. I., & Luiten, R. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4756 · Cited by 625 · cited 3×
“gen between tumor and organ- specific cells (48,49).”
BackgroundDowney, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., et al. (2015) · Kölner Universitäts PublikationsServer (Universität zu Köln) · Cited by 495
Self-citationAbdel-Wahab, N., Shah, M., Lopez-Olivo, M. A., & Suarez-Almazor, M. E. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2073 · Cited by 487 · cited 1×
“1) 21 (54) 1 (25) 0 (0) Performance status score 0–1 at start of ICI 97 (91) 61 (95) 34 (87) 2 (67) 0 (0) Metastases at start of ICI 89 (85) 51 (81) 33 (89) 3 (100) 2 (100) Preexisting autoimmune disease Psoriasis and PsA 31 (28) 20 (30) 10 (25) 1 (25) 0 (0) RA 20 (18) 8 (12) 10 (25) 2 (50) 0 (0) IBD 14 (13) 8 (12) 6…”
Abdel-Wahab, N., Shah, M., & Suarez-Almazor, M. E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0160221 · Cited by 444
Schadendorf, D., Wolchok, J. D., Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Chesney, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.2289 · Cited by 441
Self-citationAssociation of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer
Joseph, C. G., Darrah, E., Shah, A. A., Skora, A. D., Casciola-Rosen, L. A., Wigley, F. M., Boin, F., Fava, A., Thoburn, C., Kinde, I., et al. (2014) · Science · doi:10.1126/science.1246886 · Cited by 436
Tarhini, A. A., Zahoor, H., Lin, Y., Malhotra, U., Sander, C., Butterfield, L. H., & Kirkwood, J. M. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0081-1 · Cited by 394
Leonardi, G. C., Gainor, J. F., Altan, M., Kravets, S., Dahlberg, S. E., Gedmintas, L., Azimi, R., Rizvi, H., Riess, J. W., Hellmann, M. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0305 · Cited by 341 · cited 8×
“The same negative effect on tumor response has previously been described in the preexisting autoimmune disease cohort of Menzies et al (14), but not in smaller series reported by Gutzmer et al (15) and Leonardi et al (21).”
BackgroundInfluentialImmune checkpoint inhibitors in challenging populations
Johnson, D. B., Sullivan, R. J., & Menzies, A. M. (2017) · Cancer · doi:10.1002/cncr.30642 · Cited by 339 · cited 4×
“have shown that transplant patients treated with ICI experienced more graft rejections with anti–PD- 1, which activates allospecific T cells in peripheral tissues (28,29).”
BackgroundInfluentialTocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Stroud, C. R., Hegde, A., Cherry, C., Naqash, A. R., Sharma, N., Addepalli, S., Cherukuri, S., Parent, T., Hardin, J., & Walker, P. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217745144 · Cited by 331
Kostine, M., Rouxel, L., Barnetche, T., Veillon, R., Martin, F., Dutriaux, C., Dousset, L., Pham-Ledard, A., Prey, S., Beylot-Barry, M., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212257 · Cited by 306
Self-citationDanlos, F.-X., Voisin, A.-L., Dyevre, V., Michot, J.-M., Routier, E., Taillade, L., Champiat, S., Aspeslagh, S., Haroche, J., Albiges, L., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.12.008 · Cited by 300
Self-citationBelkhir, R., Burel, S. L., Dunogeant, L., Marabelle, A., Hollebecque, A., Besse, B., Leary, A., Voisin, A.-L., Pontoizeau, C., Coutte, L., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211216 · Cited by 242
Self-citationFucà, G., Galli, G., Poggi, M., Lo Russo, G., Proto, C., Imbimbo, M., Ferrara, R., Zilembo, N., Ganzinelli, M., Sica, A., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000457 · Cited by 209 · cited 5×
“Fucà et al (45) studied 35 patients who received early treatment with steroids, defined as corticosteroids ≥10 mg for at least 1 day within 28 days after ICI initiation, among”
BackgroundInfluentialGutzmer, R., Koop, A., Meier, F., Hassel, J. C., Terheyden, P., Zimmer, L., Heinzerling, L., Ugurel, S., Pföhler, C., Gesierich, A., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.038 · Cited by 205
Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade
Esfahani, K., & Miller, W. H. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1703047 · Cited by 200
Ascierto, P. A., Simeone, E., Sileni, V., Pigozzo, J., Maio, M., Altomonte, M., Del Vecchio, M., Di Guardo, L., Marchetti, P., Ridolfi, R., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-116 · Cited by 163
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment
Gajewski, T. F., Fuertes, M. B., Spaapen, R. M., Zheng, Y., & Kline, J. P. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.11.013 · Cited by 145
Friend, B. D., Venick, R. S., McDiarmid, S. V., Zhou, X., Naini, B. V., Wang, H., Farmer, D. G., Busuttil, R. W., & Federman, N. C. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26682 · Cited by 135
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
For the German Dermatologic Cooperative Oncology Group (DeCOG), Kähler, K. C., Eigentler, T., Gesierich, A., Heinzerling, L., Loquai, C., Meier, F. E., Meiß, F., Pföhler, C., Schlaak, M. S., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2134-z · Cited by 129
CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model
Yshii, L., Gebauer, C., Pignolet, B., Mauré, E., Queriault, C., Pierau, M., Saito, H., 昇, 鈴., Brunner-Weinzierl, M. C., Bauer, J., et al. (2016) · Brain · doi:10.1093/brain/aww225 · Cited by 127
Richter, M. D., Pinkston, O., Kottschade, L. A., Finnes, H. D., Markovic, S. N., & Thanarajasingam, U. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40397 · Cited by 117
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient
Herz, S., Höfer, T., Papapanagiotou, M., Leyh, J., Meyenburg, S., Schadendorf, D., Ugurel, S., Roesch, A., Livingstone, E., Schilling, B., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.07.026 · Cited by 102
Spigel, D. R., McLeod, M., Hussein, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx380.002 · Cited by 98
Tapering of Immunosuppression and Sustained Treatment With Nivolumab in a Liver Transplant Recipient
Toni, E. N. D., & Gerbes, A. L. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.063 · Cited by 83
The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma
Lee, B., Wong, A. N. M., Kee, D., Neeson, P. J., Shackleton, M. J., McArthur, G. A., & Sandhu, S. K. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw056 · Cited by 76
Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases
Calabrese, L. H., & Velcheti, V. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209782 · Cited by 75
Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy
Chapman, P. B., D’Angelo, S. P., & Wolchok, J. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1501894 · Cited by 63
Pedersen, M., Andersen, R. S., Nørgaard, P. H., Jacobsen, S., Thielsen, P., Straten, P. T., & Svane, I. M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1607-y · Cited by 58
Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge
Kostine, M., Chiche, L., Lazaro, E., Halfon, P., Charpin, C., Arniaud, D., Rétornaz, F., Blanco, P., Jourde‐Chiche, N., Richez, C., et al. (2017) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2017.01.004 · Cited by 44
Self-citationThe Bad and the Good News on Cancer Immunotherapy: Implications for Organ Transplant Recipients
Maggiore, U., & Pascual, J. (2016) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2016.08.002 · Cited by 43
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders.
Johnson, D. B., Khushalani, N. I., Puzanov, I. J., Mudigonda, T. V., Kaufman, H. L., Sosman, J. A., Mehnert, J. M., & Clark, J. I. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.9019 · Cited by 26
Cited by
Immune-related adverse events of checkpoint inhibitors
Ramos-Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suárez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,412
Self-citationThe foundations of immune checkpoint blockade and the ipilimumab approval decennial
Korman, A. J., Garrett-Thomson, S. C., & Lonberg, N. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00345-8 · Cited by 548
Kostine, M., Finckh, A., Bingham, C. O., Visser, K., Leipe, J., Schulze-Koops, H., Choy, E. H., Benesova, K., Radstake, T. R. D. J., Cope, A. P., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217139 · Cited by 290
Self-citationHaanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222
Zhou, C., Peng, S., Lin, A., Jiang, A., Peng, Y., Gu, T., Liu, Z., Cheng, Q., Zhang, J., & Luo, P. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101967 · Cited by 213
Metadata
- Authors
- Tison, A., Quéré, G., Misery, L., Funck‐Brentano, E., Danlos, F., Routier, E., Robert, C., Loriot, Y., Lambotte, O., Bonniaud, B., Scalbert, C., Maanaoui, S., Lesimple, T., Martinez, S., Marcq, M., Chouaid, C., Dubos, C., Brunet‐Possenti, F., Stavris, C., Chiche, L., Beneton, N., Mansard, S., Guisier, F., Doubre, H., Skowron, F., Aubin, F., Zehou, O., Roge, C., Lambert, M., Pham‐Ledard, A., Beylot‐Barry, M., Veillon, R., Kramkimel, N., Giacchero, D., De Quatrebarbes, J., Michel, C., Auliac, J., Gonzales, G., Decroisette, C., Le Garff, G., Carpiuc, I., Vallerand, H., Nowak, E., Cornec, D., Kostine, M., & Groupe de Cancérologie Cutanée, G. F. D. P.
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2019-10-21
- Volume
- 71
- Issue
- 12
- Pages
- 2100-2111
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W2980012328
- Cited by
- 309
- References
- 53
- FWCI
- 14.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.